Medimmune Llc

This study tested two immune-boosting drugs, durvalumab and tremelimumab, given alone or together (sometimes with a third drug, bevacizumab) in 433 adults with advanced liver cancer. The goal was to see if these treatments are safe and can shrink or slow the cancer. Participants …

This study is for people with a specific type of advanced lung cancer (EGFRm NSCLC) that has been treated before. It tests new combinations of drugs to see if they are safe and can shrink tumors. About 43 adults are taking part, and the goal is to better control the disease, not …

This early-phase study tests a new drug called MEDI5752, given alone or with chemotherapy, in adults with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 400 p…

This study tests an experimental drug called tremelimumab against a placebo in people with advanced mesothelioma that cannot be removed by surgery. About 571 adults who have already tried at least one prior treatment will be randomly assigned to receive either the drug or a place…

This study tests whether adding new cancer drugs to standard chemotherapy can better control metastatic colorectal cancer that is microsatellite-stable. About 61 adults with this advanced cancer will receive different drug combinations. The main goals are to check safety and see …